NO20050154L - Anvendelse av MGLUR5-antagonister til behandling av GERD - Google Patents

Anvendelse av MGLUR5-antagonister til behandling av GERD

Info

Publication number
NO20050154L
NO20050154L NO20050154A NO20050154A NO20050154L NO 20050154 L NO20050154 L NO 20050154L NO 20050154 A NO20050154 A NO 20050154A NO 20050154 A NO20050154 A NO 20050154A NO 20050154 L NO20050154 L NO 20050154L
Authority
NO
Norway
Prior art keywords
treatment
gerd
antagonists
mglur5 antagonists
glutamate receptor
Prior art date
Application number
NO20050154A
Other languages
English (en)
Inventor
Anders Lehmann
Thomas M Stormann
Jan Mattsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050154(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20050154L publication Critical patent/NO20050154L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

2005-01-11 SAMMENDRAG Den foreliggende oppfinnelse angår anvendelse av metabotrofe glutamatreseptor 5 antagonister til inhibisjon av transient nedre øsofagale sfinkteravslapninger. En ytterligere side av oppfinnelsen er rettet på anvendelse av metabotrofe glutamatreseptor 5 antagonister til behandling av gastro, øsofagal reflukssykdom så vel som for behandling av oppgulping og astma.
NO20050154A 2002-06-20 2005-01-11 Anvendelse av MGLUR5-antagonister til behandling av GERD NO20050154L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use
PCT/US2003/016223 WO2004000316A1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd

Publications (1)

Publication Number Publication Date
NO20050154L true NO20050154L (no) 2005-01-11

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050154A NO20050154L (no) 2002-06-20 2005-01-11 Anvendelse av MGLUR5-antagonister til behandling av GERD

Country Status (25)

Country Link
EP (1) EP1513525B1 (no)
JP (2) JP4683920B2 (no)
CN (1) CN100430056C (no)
AT (1) ATE395059T1 (no)
AU (1) AU2003241585B2 (no)
BR (1) BR0311759A (no)
CA (1) CA2489730C (no)
CY (1) CY1107954T1 (no)
DE (1) DE60320990D1 (no)
DK (1) DK1513525T3 (no)
ES (1) ES2304510T3 (no)
HK (1) HK1075833A1 (no)
IL (1) IL165138A0 (no)
IS (1) IS7654A (no)
MX (1) MXPA04012659A (no)
NO (1) NO20050154L (no)
NZ (1) NZ536559A (no)
PL (1) PL372186A1 (no)
PT (1) PT1513525E (no)
RU (1) RU2324484C2 (no)
SE (1) SE0201943D0 (no)
SI (1) SI1513525T1 (no)
UA (1) UA81627C2 (no)
WO (1) WO2004000316A1 (no)
ZA (1) ZA200409908B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
RU2381226C2 (ru) * 2004-02-18 2010-02-10 Астразенека Аб Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
CN1934097A (zh) * 2004-02-18 2007-03-21 阿斯利康(瑞典)有限公司 炔基化哌嗪化合物及其作为代谢型谷氨酸受体拮抗剂的应用
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
MX2008012413A (es) * 2006-03-29 2008-10-07 Hoffmann La Roche Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2).
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
CN102131503A (zh) 2008-06-30 2011-07-20 诺瓦提斯公司 用于治疗帕金森病的包含mGluR调节剂的组合产品
US20120157464A1 (en) 2009-07-23 2012-06-21 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
BR112012033290A2 (pt) 2010-06-24 2016-11-22 Novartis Ag uso de 1h-quinazolina-2,4-dionas
JP2014503568A (ja) 2011-01-27 2014-02-13 ノバルティス アーゲー ニコチン酸アセチルコリン受容体α７活性化因子の使用
EP2753331A1 (en) 2011-09-07 2014-07-16 Novartis AG Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
BR112015016992A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594424B2 (en) * 1986-01-03 1990-03-08 University Of Melbourne, The Gastro-oesophageal reflux composition
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
JP2002515448A (ja) * 1998-05-15 2002-05-28 アフトン・コーポレーシヨン 食道逆流病の処置法
NZ517221A (en) * 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
ATE395059T1 (de) 2008-05-15
BR0311759A (pt) 2005-03-08
ZA200409908B (en) 2006-08-30
IS7654A (is) 2005-01-19
ES2304510T3 (es) 2008-10-16
EP1513525A1 (en) 2005-03-16
WO2004000316A1 (en) 2003-12-31
PT1513525E (pt) 2008-06-24
DK1513525T3 (da) 2008-08-11
RU2005101411A (ru) 2005-07-10
SE0201943D0 (sv) 2002-06-20
EP1513525B1 (en) 2008-05-14
CA2489730A1 (en) 2003-12-31
JP4683920B2 (ja) 2011-05-18
JP2011068669A (ja) 2011-04-07
CA2489730C (en) 2011-11-22
CY1107954T1 (el) 2013-09-04
UA81627C2 (ru) 2008-01-25
DE60320990D1 (de) 2008-06-26
RU2324484C2 (ru) 2008-05-20
MXPA04012659A (es) 2006-05-25
SI1513525T1 (sl) 2008-08-31
HK1075833A1 (en) 2005-12-30
IL165138A0 (en) 2005-12-18
NZ536559A (en) 2007-08-31
AU2003241585A1 (en) 2004-01-06
PL372186A1 (en) 2005-07-11
CN100430056C (zh) 2008-11-05
AU2003241585B2 (en) 2009-06-25
CN1662235A (zh) 2005-08-31
JP2006507225A (ja) 2006-03-02

Similar Documents

Publication Publication Date Title
NO20050154L (no) Anvendelse av MGLUR5-antagonister til behandling av GERD
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
DE122012000018I1 (de) Benzimidazolderivate und ihre verwendung als antagonisten des a II rezeptors.
ATE301649T1 (de) Furan and thiophen derivate die menschliche peroxisome proliferator aktivierte receptoren aktivieren
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα
WO2007047646A3 (en) Substituted dihydro-isoindolones useful in treating kinase disorders
ITMI20021620A1 (it) Composto ad ativita' antitumorale
EA201000283A1 (ru) Новые гетероциклические соединения в качестве антагонистов метаботропных глутаматных рецепторов 5-го подтипа (мглу5)
ATE399164T1 (de) Antagonisten des opioidrezeptors
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
MA28811B1 (fr) Nouvelles utilisations de derives d'imidazotriazinones substituees par 2-phenyle
WO2003043619A8 (en) New use for the treatment of gastroesophageal reflux disease
DE60207104D1 (de) 2-amino-4-heteroarylethyl-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
NO20041595L (no) Ny kombinasjon bestaende av en PDE4 inhibitor eller en PDE3/4 inhibitor i kombinasjon med en leukotrienreseptorantagonist for behandling av luftveislidelser
MY148488A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
SE0303492D0 (sv) New use VII
PE20020052A1 (es) Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato
SE0201939D0 (sv) New combination
DE60317709D1 (de) Substituierte 1-piperidin-3-yl-4-piperidin-4-yl-piperazin-derivate und ihre verwendung als neurokinin-antagonisten
ATE447950T1 (de) Antitumorale kombination aus substituierten acryloyldistamycin-derivaten und wachstumsfaktoren oder ihre rezeptoren hemmende antikörper
SE0303491D0 (sv) New use VI
DE69922918D1 (de) Neuropeptid Y Antagonisten

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

FC2A Withdrawal, rejection or dismissal of laid open patent application